UCL 1409

Drug Profile

UCL 1409

Latest Information Update: 08 Mar 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioprojet
  • Class Analgesics; Antiepileptic drugs; Antihistamines; Neuroprotectants; Nootropics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported CNS disorders

Most Recent Events

  • 08 Mar 2000 No-Development-Reported for CNS disorders in France (Unknown route)
  • 14 May 1997 New profile
  • 14 May 1997 Preclinical development for CNS disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top